NCT02704858 2026-03-02Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated GliomaNeonc Technologies, Inc.Phase 1/2 Recruiting49 enrolled
NCT05023018 2026-03-02NEO100 and High-Grade MeningiomaNeonc Technologies, Inc.Phase 2 Recruiting30 enrolled